Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement



Status:Completed
Conditions:Infectious Disease, Hematology
Therapuetic Areas:Hematology, Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:8/31/2018
Start Date:November 2015
End Date:August 2018

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Pilot Study to Determine Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement

The main purpose of this study is to discover how 18F-cholineFCH distributes in the body, and
see if it can distinguish active histiocytes (tumor) from inflammatory (non- tumor) cells.
This tracer has the potential to give the investigators' team more information when trying to
identify the tumor cells that are most important to collect with biopsy. In addition, the
study will measure levels of 18F-cholineFCH in the biopsy tissue.


Inclusion Criteria:

- Age ≥ 18 years old

- Suspected but pathologically unconfirmed diagnosis of Erdheim-Chester disease or
Langerhans cell histiocytosis or other histiocytic disorder on the basis of clinical
diagnosis, radiologic features, or findings from prior biopsies

Or

- Confirmed diagnosis of Erdheim-Chester disease or Langerhans cell histiocytosis or
other histiocytic disorder and requiring additional diagnostic imaging and biopsy to
determine mutational status in order to determine therapeutic options.

Exclusion Criteria:

- Inability to undergo or cooperate with PET/CT scan (e.g., claustrophobia)

- Pregnant or nursing female
We found this trial at
1
site
Memoral Sloan Kettering Cancer Center
New YorK, New York 10065
Principal Investigator: Eli Diamond, MD
Phone: 212-639-7576
?
mi
from
New YorK, NY
Click here to add this to my saved trials